** AbbVie ABBV.N raised its full-year profit forecast on Friday while downplaying the potential hit some analysts expect it to take from sector-specific import duties that could be imposed by the Trump administration
** Average recommendation of 28 brokerages is "buy", median PT is $210 - data compiled by LSEG
PLAYING WITH A STRONG PIPELINE
** J.P.Morgan ("overweight") sees growth potential from newer immunology drugs Skyrizi and Rinvoq, and ABBV has the financial capacity for further business development into the 2030s
** "We see ABBV with slightly above average exposure to potential tariffs, given the company's more US-centric sales mix" - JPM
** BofA Global Research ("neutral," PO: $200) says ABBV's strength lies in having fewer patent expirations this decade, and continues to observe that consensus under model Skyrizi and Rinvoq, which could be a source of growth
** Citigroup ("buy," PT: $210) says co's strong U.S. presence could help mitigate potential near-term pharma tariffs better than expected
** Leerink Partners ("outperform", PT: $210) says "Skyrizi's U.S. supply is sourced from domestic manufacturing, and AbbVie's broad global manufacturing footprint could help mitigate the impact of tariffs"
(Reporting by Akriti Shah in Bengaluru)
((akriti.shah@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.